Filing Analysis
Femasys Inc. executed a 1-for-20 reverse stock split effective June 5, 2026, to consolidate its outstanding common stock. The split-adjusted shares are scheduled to begin trading on the Nasdaq Capital Market on June 8, 2026.
🚩 Red Flags
- Reverse stock splits are frequently used by micro-cap companies to artificially inflate share price to maintain Nasdaq minimum bid price requirements and avoid delisting.
📋 Key Facts
- Reverse split ratio is 1-for-20.
- Effective date and time: June 5, 2026, at 8:40 a.m. Eastern Time.
- Trading on a split-adjusted basis begins June 8, 2026.
- Fractional shares are rounded up to the next whole share at the DTC participant level.
- New CUSIP number: 31447E 204.
- Stock options, RSUs, and warrants were adjusted proportionately (decrease in shares, increase in exercise price).
Femasys Inc. announced a 1-for-20 reverse stock split of its common stock, effective June 5, 2026, with split-adjusted trading beginning on June 8, 2026.
🚩 Red Flags
- Reverse stock splits in micro-cap companies are frequently used to artificially inflate share price to avoid Nasdaq minimum bid price delisting requirements.
📋 Key Facts
- Reverse split ratio is 1-for-20.
- Effective date: June 5, 2026, at 4:30 p.m. ET.
- Split-adjusted trading begins: June 8, 2026.
- New CUSIP number: 31447E 204.
- Fractional shares will be rounded up to the next whole share at the DTC participant level.
- Trading symbol 'FEMY' remains unchanged.
Femasys Inc. filed an 8-K to disclose an updated corporate slide presentation for use in upcoming meetings with investors and analysts. The presentation was furnished under Item 7.01 and is intended to provide current information to the market.
📋 Key Facts
- Report date: May 13, 2026
- Item 7.01: Regulation FD Disclosure regarding an updated slide presentation
- Exhibit 99.1: Updated corporate presentation for investor and analyst meetings
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act
Femasys Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Corporate update provided in conjunction with financial results
- Filing date: May 8, 2026
- Information furnished under Item 2.02 and not deemed 'filed' for Section 18 purposes
Femasys stockholders approved a reverse stock split of up to 1-for-25 and authorized the issuance of shares exceeding 19.99% of outstanding stock related to convertible notes and warrants. The approvals facilitate significant potential dilution through anti-dilution and price adjustment provisions that may drop below the Nasdaq Minimum Price.
🚩 Red Flags
- Authorization of a significant reverse stock split (up to 1-for-25), often a sign of delisting risk or price distress.
- Approval of highly dilutive share issuances below the Nasdaq Minimum Price.
- Related-party transactions involving directors and officers in the private placements.
- Potential for massive dilution through anti-dilution and price adjustment provisions in convertible notes and warrants.
📋 Key Facts
- Stockholders approved a reverse stock split ratio between 1-for-2 and 1-for-25, to be implemented at the board's discretion before May 1, 2027.
- Approved the issuance of common stock in excess of 19.99% of outstanding shares upon conversion of senior secured convertible notes and exercise of Series A-1, B-1, C-1, and D-1 warrants.
- The issuance approval includes provisions for effective conversion or exercise prices below the Nasdaq Minimum Price.
- The underlying private placements included participation by directors and officers of the company.
- The Special Meeting of Stockholders was held on April 29, 2026, with 39.91% of eligible shares represented.
Femasys Inc. appointed John Canning as Chief Operating Officer, effective March 30, 2026. Mr. Canning, a former COO at Terumo Aortic, will receive a $450,000 base salary and 150,000 inducement stock options.
📋 Key Facts
- John Canning appointed as COO effective March 30, 2026
- Annual base salary of $450,000 with a 40% target bonus
- Inducement grant of 150,000 stock options outside the 2021 Equity Incentive Plan
- Canning previously served as COO at Terumo Aortic (2017-2026) and held roles at Medtronic
- Severance includes 9 months of base salary and COBRA premiums
Femasys Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a corporate update. The announcement was furnished via a press release on March 31, 2026.
📋 Key Facts
- The filing was made on March 31, 2026, reporting results for the fiscal year ended December 31, 2025.
- The report includes a corporate update in addition to financial results.
- The information is furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed 'filed' for statutory purposes.
- Femasys Inc. is identified as an emerging growth company.
Femasys Inc. entered into an omnibus amendment with lenders to remove share combination adjustment provisions in existing convertible notes and warrants, issuing over 16 million new warrants as consideration. Concurrently, the lead lender exercised its contractual right to appoint a new director to the board following a resignation.
🚩 Red Flags
- Issuance of a massive volume of warrants (16,378,563) as consideration for a technical amendment to debt terms.
- Removal of 'Share Combination Event Adjustment' language often signals an impending or recently completed reverse stock split.
- Lender-controlled board seat indicates significant creditor influence over corporate governance.
- Multiple 8-K items (1.01, 3.02, 5.02) triggered in a single filing.
📋 Key Facts
- Entered into an Omnibus Amendment and Consent Agreement on March 19, 2026, with holders of Senior Secured Convertible Notes.
- The amendment removes the 'Share Combination Event Adjustment' in existing Notes and Warrants effective December 31, 2025.
- Issued 16,378,563 Series D-1 Warrants to lenders as consideration for the amendment, with an exercise price of $0.58 per share.
- Director Joshua Silverman resigned effective March 17, 2026.
- Dr. Kenneth D. Eichenbaum was appointed to the Board on March 18, 2026, pursuant to a nomination right held by Pointillist Partners LLC (the Lead Lender).
- Pointillist Partners LLC's nomination right remains active as long as they own at least 4.99% of the company or until the notes are paid in full.